Ownership network

Asserters.

Every entity that has appeared as an assignee on a tracked US patent. Built from structured records extracted from each patent’s assignment-history dossier. Click any column header to sort; defaults to most cases filed. Entities markedNPE orshell LLC are flagged this way by the model from the patent dossier — known asserter lists, no products in commerce, registered-agent addresses, single-purpose Delaware/Texas LLCs. These classifications are inferences, not determinations, and may be wrong — treat an entity marked NPE or shell LLC as a possible one, to verify, not a confirmed one.

3 possible patent-rental round-trips — patents that moved A → B → A while B filed at least one infringement suit during its tenure. The round-trip is a structural pattern, not proof of intent: it can also reflect a security interest and release, a correction, or a financing deal. Flagged rows are marked below — treat them as leads to verify.

EntityTypePatents nowPatents everCases filedConnectionsFlags
Nagai, Yasuhiko; Fujiyama, Tatsuya; Arai, Masato; Tsunoda, Mitsuhiro; Yamada, Tomoakiindividual0001
Marcello Peppi; Vishal Tandonindividual0001
Luis Velasques Garciaindividual0001
Ashley Beckwith; Nathan Moore; Daniel Doty; Jeffrey Borensteinindividual0001
Johnson Lau; Jean-Luc Girardet; Zhi Hong; Kanda S. Ramasamyindividual0001
Aton Pharma, Inc.; Coria Laboratories, Ltd.; Dow Pharmaceutical Sciences, Inc.; Valeant Pharmaceuticals International; Valeant Pharmaceuticals North Americaoperating co0001
Prestwick Pharmaceuticals, Inc.; Valeant Biomedicals, Inc.; Valeant Pharmaceuticals International; Valeant Pharmaceuticals North America LLCoperating co0001
Kadmon Corporation LLCoperating co0002
Bausch & Lomb Incorporated; Bausch Health Americas, Inc.; Bausch Health US, LLC; Medicis Pharmaceutical Corporation; OraPharma, Inc.; Precision Dermatology, Inc.; Salix Pharmaceuticals, Inc.; Salix Pharmaceuticals, Ltd.; Santarus, Inc.; Solta Medical, Inc.operating co0001
Bausch Health Companies Inc.; Bausch Health Ireland Limited; Bausch Health, Canada Inc.; Technolas Perfect Vision GmbH; Valeant Pharma Poland; Valeant Pharmaceuticals Luxembourg S.à r.l.; Valeant Sp. z o.o.operating co0001
Barclays Bank PLC, as Collateral Agent—0001
Juan Ricafort; Harkirat Singh; Philip Martinindividual0001
SABAN, Daniel; DANA, Rezaindividual0001
Gustav Vlahos; Robert B. Jonesindividual0001
Dimitriy Rozenblit; William J. Domino; Morton Damgaard; Nooshin D. Vakilianindividual0001
Jeffrey Alston; Andrew Guenthner; Joseph Mabryindividual0001
Chia-Sam Weyindividual0001
Leslie B. Lamportindividual0001
Se-Youn Lim, Seo-Won Kwon, Jin-Hee Kim, Jae-Yeon Song, Yoon-Sun Lee, Jong-Hwa Leeindividual0001
Newberg, Fredric; Gelvin, David C.; Girod, Lewis D.; Kaiser, William J.; Merrill, William M.; Pottie, Gregory C.; Sipos, Anton I.; Vardhan, Sandeepindividual0001
Hummer Winblad Venture Partners IV, L.P.; Hummer Winblad Technology Fund IV, L.P.; Bruggere, Thomas—0001
Bruggere, Thomas; Hummer Winblad Technology Fund IV, L.P.; Hummer Winblad Venture Partners IV, L.P.—0001
Chambers, Seanindividual0001
Aggerholm, Steen; Hansen, Palle Mindividual0001
Karimi, Farzin; Crosby, Thompson W.; Irrinki, V. Swamyindividual0001